Business Wire

Bobbi Brown Cosmetics Announces Sara Foster as Global Brand Ambassador

14.10.2025 15:32:00 CEST | Business Wire | Press Release

Share

Bobbi Brown Cosmetics is proud to announce actress, entrepreneur, and podcast host Sara Foster as its newest Global Ambassador, marking the beginning of a long-term partnership that will spotlight the brand’s “Effortlessly Put-Together” campaign and celebrate its timeless philosophy of confidence through simplicity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251014443911/en/

Known for her sharp humor, relatable candor, and modern take on beauty, Sara has become a voice for women seeking balance amid busy, multifaceted lives. As co-founder of the fashion label Favorite Daughter, co-host of the hit podcast The World’s First Podcast, executive producer of Netflix’s Nobody Wants This, and a devoted mother, she embodies the Bobbi Brown ethos: real beauty that works for real life.

“Bobbi Brown has always celebrated real women and real beauty, and that’s what drew me to this partnership,” said Sara Foster. “The products are effortless, reliable, and they make you feel confident in your own skin.”

Launching globally in October 2025, Sara’s debut campaign — Effortlessly Put-Together — highlights three of Bobbi Brown’s most loved products: Long-Wear Cream Shadow Stick, Skin Corrector Stick, and Extra Plump Lip Serum. Designed for women who want to look polished in minutes, the campaign captures Sara’s straightforward, no-fuss approach to beauty.

“Sara embodies the ease, humor, and authenticity that define Bobbi Brown. She has long been known for her quick wit and effortlessly polished sense of style,” said Lahnie Strange, Senior Vice President and General Manager, Bobbi Brown Cosmetics. “She’s achieved so much, yet approaches it all with humor and self-awareness, and that balance perfectly reflects how we see beauty at Bobbi Brown: confident, modern, and never overcomplicated.”

The partnership will extend across social, digital, and retail channels, featuring exclusive behind-the-scenes content, storytelling in Sara’s voice, and continued emphasis on products that empower women to feel confident and put-together — effortlessly.

Follow @BobbiBrown and @SaraFoster for more on the partnership.

About Sara Foster

Sara Foster is a comedic actress, producer, and entrepreneur. She is the co-founder of the contemporary fashion label Favorite Daughter, co-hosts the award-winning podcast The World’s First Podcast, and an executive producer of the acclaimed Netflix series Nobody Wants This. The show has been nominated for Golden Globes, Emmys, Critics Choice Awards, and is an AFI Awards Honoree. After the success of the first season, Foster alongside her sister Erin signed an overall deal with 20th Television, under the Disney umbrella, to develop new projects. In addition to her work in entertainment and fashion, Foster co-founded Oversubscribed Ventures, a fund investing in leading consumer and technology brands. In October 2025, she was named Global Ambassador for Bobbi Brown Cosmetics.

About Bobbi Brown

EFFORTLESS MAKEUP. NATURAL BEAUTY.

Founded by a New York makeup artist in 1991, we helped change the face of beauty with a natural approach to makeup that rallied everyone to not only be who you are—but own how you look.

And while our roots are in artistry, our aim has always been ease. Life-proof products, just-right shades, and effortless routines that enhance your beauty. Because putting a few products together is all it should take to feel put-together.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251014443911/en/

Contacts

EILEEN DAUTRUCHE edautruc@estee.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye